Editorial Standards

Latest News Today maintains rigorous editorial standards. Our team verifies information from trusted sources and provides context to help readers understand complex stories.

Last Updated: Thursday, October 1, 2026 at 06:42 PM
Category: Health

Editor's Note

Latest News Today provides comprehensive coverage and analysis of breaking news stories. This article is part of our ongoing coverage of generic version risperdal gains fda ok flna1C9462061, bringing you verified information from trusted sources with added context and expert perspective.

Why This Matters: Understanding the full context of this story helps readers make informed decisions and stay updated on developments that impact our community.

Generic version of Risperdal gains FDA OK

Johnson & Johnson's blockbuster anti-psychotic drug Risperdal will face generic competition, as Teva Pharmaceutical Industries Ltd. on Monday became the first company to receive approval for a generic version.

Israel-based Teva received Food and Drug Administration approval for a generic version of the blockbuster drug, used to treat schizophrenia and bipolar disorder, among other conditions. New Brunswick, N.J.-based Johnson & Johnson's Janssen unit had expected Risperdal's patent expiration this month, followed by tough generic competition over the key revenue driver.